Drug Type CAR-T |
Synonyms Allogeneic Logic-gated CAR T(A2 Biotherapeutics) |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of large intestine | Phase 2 | United States | 31 Mar 2025 | |
Colonic Cancer | Phase 2 | United States | 31 Mar 2025 | |
Non-Small Cell Lung Cancer | Phase 2 | United States | 31 Mar 2025 | |
Rectal Cancer | Phase 2 | United States | 31 Mar 2025 | |
Renal Cell Carcinoma | Phase 2 | United States | 31 Mar 2025 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | United States | 31 Mar 2025 | |
Triple Negative Breast Cancer | Phase 2 | United States | 31 Mar 2025 |